BRPI0814548A2 - Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila - Google Patents

Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila

Info

Publication number
BRPI0814548A2
BRPI0814548A2 BRPI0814548-2A2A BRPI0814548A BRPI0814548A2 BR PI0814548 A2 BRPI0814548 A2 BR PI0814548A2 BR PI0814548 A BRPI0814548 A BR PI0814548A BR PI0814548 A2 BRPI0814548 A2 BR PI0814548A2
Authority
BR
Brazil
Prior art keywords
amino
dimethylphylen
benzonitril
cyanoethenyl
pyrimidinyl
Prior art date
Application number
BRPI0814548-2A2A
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Elisabeth Maria Helene Egide Ghislaine Theunissen
Lieven Elvire Colette Baert
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38706528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814548(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0814548A2 publication Critical patent/BRPI0814548A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0814548-2A2A 2007-07-12 2008-07-11 Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila BRPI0814548A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07112392 2007-07-12
PCT/EP2008/059054 WO2009007441A2 (en) 2007-07-12 2008-07-11 Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile

Publications (1)

Publication Number Publication Date
BRPI0814548A2 true BRPI0814548A2 (pt) 2015-01-06

Family

ID=38706528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814548-2A2A BRPI0814548A2 (pt) 2007-07-12 2008-07-11 Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila

Country Status (15)

Country Link
US (1) US8426434B2 (pt)
EP (1) EP2175857B1 (pt)
JP (1) JP5701057B2 (pt)
CN (1) CN101743006B (pt)
AU (1) AU2008274185B2 (pt)
BR (1) BRPI0814548A2 (pt)
CA (1) CA2693044C (pt)
DK (1) DK2175857T3 (pt)
ES (1) ES2437331T3 (pt)
HK (1) HK1144669A1 (pt)
HR (1) HRP20131128T1 (pt)
IL (1) IL202363A (pt)
RU (1) RU2498979C2 (pt)
SI (1) SI2175857T1 (pt)
WO (1) WO2009007441A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
ES2530941T3 (es) * 2009-09-22 2015-03-09 Janssen Sciences Ireland Uc Tratamiento y prevención de infección por el VIH
US20120295898A1 (en) * 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
CN108210469A (zh) 2011-04-15 2018-06-29 詹森药业有限公司 冻干药物纳米混悬剂
EP2604593A1 (en) * 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) * 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
WO2013087794A1 (en) * 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EA201590862A1 (ru) * 2012-12-14 2016-05-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Фармацевтические композиции
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
FI3597646T3 (fi) 2016-08-19 2023-09-07 Gilead Sciences Inc Hi-virusinfektion profylaktiseen tai terapeuttiseen hoitoon käyttökelpoisia terapeuttisia yhdisteitä
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2493794C (en) 2002-08-09 2010-05-25 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NZ540321A (en) 2002-11-15 2007-09-28 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0609299A2 (pt) * 2005-04-13 2010-03-23 Pfizer Prod Inc formulaÇÕes de depàsito injetÁveis e mÉtodos para proporcionar liberaÇço sustentada de composiÇÕes de nanopartÍculas

Also Published As

Publication number Publication date
HRP20131128T1 (hr) 2013-12-20
HK1144669A1 (pt) 2011-03-04
IL202363A (en) 2016-04-21
DK2175857T3 (da) 2013-12-02
WO2009007441A3 (en) 2009-04-30
JP2010533148A (ja) 2010-10-21
SI2175857T1 (sl) 2014-01-31
WO2009007441A2 (en) 2009-01-15
CN101743006B (zh) 2013-09-11
CA2693044A1 (en) 2009-01-15
US20100189796A1 (en) 2010-07-29
AU2008274185B2 (en) 2014-07-03
JP5701057B2 (ja) 2015-04-15
IL202363A0 (en) 2010-06-30
CN101743006A (zh) 2010-06-16
AU2008274185A1 (en) 2009-01-15
CA2693044C (en) 2017-03-14
ES2437331T3 (es) 2014-01-10
EP2175857B1 (en) 2013-09-11
RU2498979C2 (ru) 2013-11-20
EP2175857A2 (en) 2010-04-21
US8426434B2 (en) 2013-04-23
RU2010104848A (ru) 2011-08-20

Similar Documents

Publication Publication Date Title
BRPI0814548A2 (pt) Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
CO6811863A2 (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
CY2016051I1 (el) Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
ES2465673T9 (es) Derivados de pirimidina
ZA201108779B (en) Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
IL218543A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
ZA201003875B (en) Novel pyrimidine derivatives
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ZA200808364B (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
IL226474A0 (en) Crystal forms of 5-chloro-n2-@@-isopropoxy-@-methyl-4-piperidine-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]pyrimidine-4,2-diamine
IL216280A0 (en) Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4-(dimethylamino)butyl 2-(4-(2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate
HK1150605A1 (en) 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
CU20090141A7 (es) Compuestos 2-amino pirimidina
BRPI0916679A2 (pt) 5-alquinil-pirimidinas
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
BRPI1013493A2 (pt) composto de pirimidina
HK1215434A1 (zh) 取代的嘧啶衍生物

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]